Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nanogen, a developer of molecular and rapid diagnostic products, has entered into an agreement with A Menarini Diagnostics, a division of The Menarini Group, the Italian pharmaceutical and diagnostics group, to commercialize CE marked in vitro diagnostic infectious disease kits based on Nanogen's proprietary MGB technology.
Subscribe to our email newsletter
Under the terms of the agreement the kits will be manufactured by Nanogen and branded as Menarini products. The first products are expected to be introduced to the market in 2009 and will target infectious disease diagnostics.
The arrangement combines Nanogen’s strength in real-time PCR in vitro diagnostic (IVD) product development with Menarini’s significant market presence in the major EU countries and their expanding reach into the developing Eastern European markets.
Howard Birndorf, CEO of Nanogen, said: “Molecular diagnostics is a high growth segment of the global IVD market and real-time PCR has become a gold standard diagnostic technology. We are pleased to have a partner like Menarini that can help bring our innovative technology to the $1 billion European market.
“We believe our strong technology and product capabilities together with Menarini’s local sales strength will open a new market and revenue stream for Nanogen and will make a highly competitive offering in Europe.”